Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097147 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo
A Phase 1 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 202
- Enrollment target
NCT02097147 is a Phase 1 study that has completed, run by Forest Laboratories. The registered enrollment target is 202 participants.
The verdict
NCT02097147, a Phase 1 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 202 participants
- Enrollment target
Study Summary
To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually active healthy adults.
Interventions
- DRUG Placebo
- DRUG Vilazodone 20 mg
- DRUG Vilazodone 40 mg
- DRUG Paroxetine 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097147
The ClinicalTrials.gov registry entry for NCT02097147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02097147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097147 about?
NCT02097147 is a clinical study titled "Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo". To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually active healthy adults.
What is the current status of trial NCT02097147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 202 participants. The study started on 2014-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02097147?
The interventions under investigation include: Placebo (DRUG), Vilazodone 20 mg (DRUG), Vilazodone 40 mg (DRUG), Paroxetine 20 mg (DRUG).
Who is sponsoring clinical trial NCT02097147?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.